The role of gut bacteria in organ damage for sickle cell disease
The microbiome determines organ damage development in sickle cell disease
This study is looking at how the bacteria in your gut might affect organ damage in people with sickle cell disease, and it hopes to find new ways to improve health by changing these bacteria through diet or other methods.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10915724 on NIH RePORTER |
What this research studies
This research investigates how the microbiome, or gut bacteria, affects the development of organ damage in patients with sickle cell disease (SCD). By studying mice with SCD, researchers have found that certain bacteria may contribute to organ damage, while reducing these bacteria can improve health outcomes. The study aims to explore the potential of manipulating gut bacteria as a new treatment approach for SCD over a five-year period. Patients may be involved in trials that test dietary changes or other interventions aimed at altering their microbiome.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with sickle cell disease, particularly those experiencing complications related to organ damage.
Not a fit: Patients without a diagnosis of sickle cell disease or those who do not have significant organ damage may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly reduce organ damage and improve the quality of life for patients with sickle cell disease.
How similar studies have performed: Previous studies have shown promising results in manipulating the microbiome for various health conditions, suggesting potential for success in this novel approach for sickle cell disease.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Li, Huihui — Icahn School of Medicine at Mount Sinai
- Study coordinator: Li, Huihui
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.